BioAge Labs (NAS: BIOA)

The AI engine Fit Assessment

Beta

BioAge is a biotechnology company focused on discovering and developing therapeutics to address aging and related diseases. Their mission is to extend healthy lifespan by targeting the molecular causes of aging through a diverse portfolio of drugs.

Blurb

BioAge Labs is a clinical-stage biotechnology company that develops therapeutics to treat obesity and metabolic diseases.

HQ Location

United States

Founded

2015

Employees

51 - 200

Total funding raised

$908.91M

Last Funding Event

IPO, $615.01M, September 26, 2024

Smart insights

  • 6m headcount growth: 7%
  • 1Y headcount growth: 13%
  • Headcount-to-last-round ratio: 4.0 employees/$M

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.